Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$66.80 - $107.17
Previous CloseN/A
Volume5.49M
Average Volume (3M)7.98M
Market Cap
$146.96B
Enterprise Value$144.04B
Total Cash (Recent Filing)$519.00M
Total Debt (Recent Filing)$5.92B
Price to Earnings (P/E)80.9
Beta0.79
Next Earnings
Apr 23, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.25
Shares Outstanding1,479,070,200
10 Day Avg. Volume6,831,470
30 Day Avg. Volume7,981,808
Financial Highlights & Ratios
PEG Ratio4.80
Price to Book (P/B)N/A
Price to Sales (P/S)8.87
Price to Cash Flow (P/CF)25.50
P/FCF Ratio29.60
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.54
Enterprise Value/Ebitda37.29
Forecast
1Y Price Target
$120.32Price Target Upside18.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
Market DemandGlobal FARAPULSE sales exceeded $1bn globally, led by uptake in US and EMEA, indicating strong market demand and growth potential.
Product EfficacyFarapulse had superior efficacy to MDT’s cryoballoon with lower AF recurrence and similar low complication rates.
Revenue GrowthBoston Scientific has consistently finished above the initial guidance range's high-end in every year since 2021.
Bears Say
Acquisition CostBSX announced an agreement to acquire SoniVie for an upfront payment of $360M and a milestone payment of up to $180M upon a regulatory milestone.
Competitive RiskChinese peers may manufacture similar products at a fraction of the cost, posing a risk to Boston's business.
Financial ImpactBSX expects the deal to be slightly dilutive to its 2025E adjusted EPS.
---
Ownership Overview
0.18% Insiders
29.79% Mutual Funds
19.10% Other Institutional Investors
29.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $66.80 and its highest was $107.17 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $146.96B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Apr 23, 2025 which is in 21 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Feb 05, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.657 by $0.043.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.67.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,479,070,200 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.7 in its last earnings report, beating expectations of $0.657. Following the earnings report the stock price went up 1.381%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
---
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.32 (18.85% Upside)
$120.32 (18.85% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 78%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.29%
12-Months-Change
Fundamentals
Return on Equity
9.03%
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
---
BSX Company Deck
---
BSX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong operational and financial performance with significant growth in key areas such as electrophysiology and Watchmen sales. Despite challenges in China and currency impacts, the company exceeded its financial guidance and demonstrated solid strategic execution.Read More>---
BSX Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
---
BSX Stock 12 Month Forecast
Average Price Target
$120.32
▲(18.85% Upside)
Technical Analysis
Abbott Laboratories
―
Intuitive Surgical
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Best Analysts Covering BSX
1 Year
1 Year Success Rate
21/22 ratings generated profit
1 Year Average Return
+33.53%
reiterated a buy rating 2 months ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 95.45% of your transactions generating a profit, with an average return of +33.53% per trade.
---